Precision Medicine Intervention in Severe Asthma (PRISM) Clinical Study

The PRISM Clinical Study is an international, multi-center research effort with an ambitious objective: to drastically reduce the frequency and severity of asthma attacks in individuals suffering from severe asthma by employing precision medicine. The study uses the principles of precision medicine, which uses information about a person's genes, proteins, and environment to prevent, diagnose, and treat disease. In asthma, precision medicine aims to tailor treatments based on an individual's unique profile, thus improving efficacy and minimizing side effects.

The PRISM study commenced in 2022 and is projected to conclude in 2026. The study is being sponsored by a consortium of universities, research institutions, and pharmaceutical companies, and is subject to oversight by institutional review boards and ethics committees.

Study Design

The PRISM study utilizes a randomized, controlled, double-blind design to eliminate bias and provide a high level of evidence on the efficacy of precision interventions. The participants, all of whom have severe asthma, are divided into two groups. The control group receives standard care, while the experimental group receives personalized treatment plans developed based on their unique genetic and environmental profiles.

Data from a range of sources is used to develop these personalized plans, including:

• Genomic sequencing to identify relevant genetic variants
• Detailed environmental exposure histories
• Comprehensive assessments of lung function and inflammation
• Regular monitoring of symptoms and quality of life

Preliminary Results

While the study is ongoing, preliminary results released in 2023 indicated that the PRISM approach has the potential to significantly improve the lives of people with severe asthma. Participants in the experimental group experienced fewer and less severe asthma attacks compared to the control group. Furthermore, these participants reported higher quality of life scores and fewer side effects from medication.

Future Implications

The PRISM Clinical Study is expected to bring about a revolution in the management of severe asthma. The study will provide valuable evidence on the efficacy of precision medicine approaches in reducing asthma attacks and improving quality of life in patients with severe asthma. It will also help to identify new therapeutic targets and contribute to the development of novel treatments for severe asthma.

Furthermore, the PRISM study has broader implications for the field of precision medicine. Its innovative use of personalized medicine in a common, chronic disease like asthma provides a model for the application of precision medicine in other diseases.

See Also

• Asthma
• Precision Medicine
• Clinical Trials
• Genomic sequencing

References

Precision Medicine Intervention in Severe Asthma (PRISM) Clinical Study Resources
Latest articles Most recent articles Ongoing trials	Wikipedia